Compare Cytokinetics Inc (CYTK) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Snap On Incorporated — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Snap On Incorporated trades at $404.38 (market cap $20.96B). The key difference: Snap On Incorporated is the larger of the two by market cap, and Snap On Incorporated pays a 2.41% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | SNA | |
|---|---|---|
Market Cap | $11.12B | $20.96B |
Sector | Technology | Technology |
52-Week High | $87.26 | $413.62 |
52-Week Low | $33.23 | $313.01 |
Enterprise Value | $11.59B | $20.48B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Snap-on Incorporated (SNA) trades at $401.11, down 0.21% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong profitability with a 19.6% net income margin and ROE of 17.83%, while recent acquisitions like Diesel Laptops for $100 million aim to expand heavy-duty diagnostics capabilities. Q1 2026 earnings missed expectations slightly, but Q2 results are anticipated.
Outlook remains positive with analyst consensus favoring Buy ratings (64.71%) and a $407.50 price target, though risks include margin pressures and muted growth forecasts. The stock offers stability with consistent dividends and share repurchases, but investors should monitor competitive and economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
